Neo-Angin (Benzydamine Hydrochloride)

Benzydamine Hydrochloride exerts its effect by inhibiting the release of pro‑inflammatory cytokines, stabilising cell membranes, and providing a mild local anesthetic action on peripheral nerve endings. This combination reduces swelling, redness and pain directly at the site of application without significant systemic absorption.

The dosage of Neo‑Angin is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical judgment. The prescriber will specify the amount to be applied and the frequency of use; patients should follow that guidance exactly and not alter the regimen on their own.

Safety data for Benzydamine Hydrochloride in pregnancy and lactation are limited. It is classified as ‘unknown’ for both conditions, so it should only be used if the potential benefit justifies the possible risk. Women who are pregnant or breastfeeding should discuss use with their physician before starting treatment.

To place an order, submit an enquiry on the Neo‑Angin product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Neo‑Angin (Benzydamine Hydrochloride) is a topical NSAID with local anesthetic properties, whereas many alternative oral analgesics such as lidocaine gels provide only numbing without anti‑inflammatory action. Compared with chlorhexidine mouthwashes, Neo‑Angin focuses on symptom relief rather than antimicrobial activity, making it a distinct option for inflammation‑driven oral discomfort.

Neo‑Angin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain stability and efficacy.

Neo‑Angin is applied directly to the affected oral mucosa. The patient should dispense the recommended amount onto the tongue or into the throat, swish gently if instructed, and retain it for a short period before expectorating or swallowing as directed by the prescriber.

The most serious risks include hypersensitivity reactions such as rash, urticaria, angioedema, and in rare cases anaphylaxis. Severe local irritation or ulceration may also occur. Any signs of allergic response or worsening oral lesions should prompt immediate discontinuation and medical evaluation.

Neo‑Angin should be avoided by individuals with a known hypersensitivity to Benzydamine Hydrochloride or any excipients in the formulation. It is also contraindicated in patients for whom the prescriber determines that the risk outweighs the benefit, such as certain children under six years of age or pregnant women without medical advice.